tetano
Editor, Senior Moderator
Encephalitis
. 2023 Aug 25.
doi: 10.47936/encephalitis.2023.00066. Online ahead of print. A case of hyperacute postvaccinal encephalopathy after BNT162b2 nCoV-19 vaccine
Soo Ji Yoon[SUP] 1 2 [/SUP], Kwang Ki Kim[SUP] 1 2 [/SUP], Hang-Rai Kim[SUP] 1 2 [/SUP], Eun Ja Lee[SUP] 3 2 [/SUP]
Affiliations
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic contributed to the development of a large variety of vaccines, of which postvaccinal hyperacute encephalopathy is a very rare complication. Despite its rarity, if diagnosed properly, appropriate treatment can be rapidly applied. A healthy 53-year-old woman was admitted for a seizure on the day she received the second dose of the BNT 162b2 nCoV-19 vaccine. She subsequently developed irritability, which gradually worsened over several days. Cerebrospinal fluid analysis revealed mild pleocytosis and normal protein levels. Brain magnetic resonance imaging (MRI) revealed diffuse sulcal hyperintensity on the entire brain surface on fluid-attenuated inversion recovery (FLAIR) images with meningeal enhancement. The patient was diagnosed with hyperacute postvaccinal encephalopathy and received immunosuppressive therapy with corticosteroids and therapeutic plasmapheresis. Fortunately, the patient responded to therapy, achieving almost complete recovery from the neurological symptoms, with only mild memory impairment remaining after 3 weeks. Based on the clinical presentation, electroencephalogram findings, and MRI, our patient developed hyperacute encephalopathy within 24 hours of vaccine administration, which we surmised from the temporal course of symptoms and brain imaging findings. Further studies are required to elucidate the pathogenesis of coronavirus disease 2019 (COVID-19) vaccination-related encephalopathy.
Keywords: COVID-19 vaccine; Post-vaccinal encephalitis; Seizure.
. 2023 Aug 25.
doi: 10.47936/encephalitis.2023.00066. Online ahead of print. A case of hyperacute postvaccinal encephalopathy after BNT162b2 nCoV-19 vaccine
Soo Ji Yoon[SUP] 1 2 [/SUP], Kwang Ki Kim[SUP] 1 2 [/SUP], Hang-Rai Kim[SUP] 1 2 [/SUP], Eun Ja Lee[SUP] 3 2 [/SUP]
Affiliations
- PMID: 37621190
- DOI: 10.47936/encephalitis.2023.00066
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic contributed to the development of a large variety of vaccines, of which postvaccinal hyperacute encephalopathy is a very rare complication. Despite its rarity, if diagnosed properly, appropriate treatment can be rapidly applied. A healthy 53-year-old woman was admitted for a seizure on the day she received the second dose of the BNT 162b2 nCoV-19 vaccine. She subsequently developed irritability, which gradually worsened over several days. Cerebrospinal fluid analysis revealed mild pleocytosis and normal protein levels. Brain magnetic resonance imaging (MRI) revealed diffuse sulcal hyperintensity on the entire brain surface on fluid-attenuated inversion recovery (FLAIR) images with meningeal enhancement. The patient was diagnosed with hyperacute postvaccinal encephalopathy and received immunosuppressive therapy with corticosteroids and therapeutic plasmapheresis. Fortunately, the patient responded to therapy, achieving almost complete recovery from the neurological symptoms, with only mild memory impairment remaining after 3 weeks. Based on the clinical presentation, electroencephalogram findings, and MRI, our patient developed hyperacute encephalopathy within 24 hours of vaccine administration, which we surmised from the temporal course of symptoms and brain imaging findings. Further studies are required to elucidate the pathogenesis of coronavirus disease 2019 (COVID-19) vaccination-related encephalopathy.
Keywords: COVID-19 vaccine; Post-vaccinal encephalitis; Seizure.